Page 115 - 《中国药房》2024年13期

指标采用中位数表达，应用Cochrane提供的计算公式间 bias in randomised trials[J]. BMJ，2011，343：d5928.
接获取的均数及标准差进行分析，该计算方法可能存在 [11] AYOB N，MUHAMMAD NAWAWI K N，MOHAMAD
误差；（5）纳入研究中仅有3项研究报道了益生菌对肠道 NOR M H，et al. The effects of probiotics on small intesti‐
菌群的调节作用 [14―16] ，但由于指标无法有效量化和统 nal microbiota composition，inflammatory cytokines and
一，未纳入本次Meta分析。因此，今后仍需开展更多大 intestinal permeability in patients with non-alcoholic fatty
liver disease[J]. Biomedicines，2023，11（2）：640.
规模、高质量的临床试验，进一步明确特定剂量、治疗时
[12] CHONG P L，LAIGHT D，ASPINALL R J，et al. A ran‐
间、不同益生菌菌株的疗效以及安全性，以全面了解益
domized placebo controlled trial of VSL#3 probiotic on
®
生菌、肠道微生态和NAFLD之间的相互作用机制。
biomarkers of cardiovascular risk and liver injury in non-
参考文献
alcoholic fatty liver disease[J]. BMC Gastroenterol，2021，
[ 1 ] NGUYEN V H，LE I，HA A，et al. Differences in liver and 21（1）：144.
mortality outcomes of non-alcoholic fatty liver disease by [13] MOHAMAD NOR M H，AYOB N，MOKHTAR N M，et
race and ethnicity：a longitudinal real-world study[J]. Clin al. The effect of probiotics （MCP BCMC strains） on he‐
®
®
Mol Hepatol，2023，29（4）：1002-1012. patic steatosis，small intestinal mucosal immune function，
[ 2 ] FENG G，VALENTI L，WONG V W，et al. Recompensa‐ and intestinal barrier in patients with non-alcoholic fatty
tion in cirrhosis：unraveling the evolving natural history of liver disease[J]. Nutrients，2021，13（9）：3192.
nonalcoholic fatty liver disease[J]. Nat Rev Gastroenterol [14] SCORLETTI E，AFOLABI P，MILES E，et al. Investiga‐
Hepatol，2024，21（1）：46-56. tion of synbiotic treatment in non-alcoholic fatty liver
[ 3 ] YOUNOSSI Z M，GOLABI P，PAIK J M，et al. The disease （INSYTE study）：a double-blind，randomised，
global epidemiology of nonalcoholic fatty liver disease placebo-controlled，phase 2 trial[J]. Gastroenterology，
（NAFLD） and nonalcoholic steatohepatitis （NASH）：a 2020，158（6）：1597-1610.
systematic review[J]. Hepatology，2023，77（4）：1335- [15] CAI G S，SU H，ZHANG J. Protective effect of probiotics
1347. in patients with non-alcoholic fatty liver disease[J]. Medi‐
[ 4 ] POURTEYMOUR S，DREVON C A，DALEN K T，et al. cine （Baltimore），2020，99（32）：e21464.
Mechanisms behind NAFLD：a system genetics perspec‐ [16] BEHROUZ V，ARYAEIAN N，ZAHEDI M J，et al. Ef‐
tive[J]. Curr Atheroscler Rep，2023，25（11）：869-878. fects of probiotic and prebiotic supplementation on meta‐
[ 5 ] JAYACHANDRAN M，QU S. Non-alcoholic fatty liver bolic parameters，liver aminotransferases，and systemic in‐
disease and gut microbial dysbiosis：underlying mecha‐ flammation in nonalcoholic fatty liver disease：a rando-
nisms and gut microbiota mediated treatment strategies[J]. mized clinical trial[J]. J Food Sci，2020，85（10）：3611-
Rev Endocr Metab Disord，2023，24（6）：1189-1204. 3617.
[ 6 ] LUTHER J，GARBER J J，KHALILI H，et al. Hepatic in‐ [17] AHN S B，JUN D W，KANG B K，et al. Randomized，
jury in nonalcoholic steatohepatitis contributes to altered double-blind，placebo-controlled study of a multispecies
intestinal permeability[J]. Cell Mol Gastroenterol Hepa‐ probiotic mixture in nonalcoholic fatty liver disease[J].
tol，2015，1（2）：222-232. Sci Rep，2019，9（1）：5688.
[ 7 ] ARON-WISNEWSKY J， WARMBRUNN M V， [18] DUSEJA A，ACHARYA S K，MEHTA M，et al. High po‐
NIEUWDORP M，et al. Nonalcoholic fatty liver disease： tency multistrain probiotic improves liver histology in
modulating gut microbiota to improve severity?[J]. Gastro‐ non-alcoholic fatty liver disease （NAFLD） ：a ran‐
enterology，2020，158（7）：1881-1898. domised，double-blind，proof of concept study[J]. BMJ
[ 8 ] BANERJEE G，PAPRI S R，SATAPATHY S K，et al. Ak‐ Open Gastroenterol，2019，6（1）：e000315.
kermansia muciniphila ：a potential next-generation probio- [19] KOBYLIAK N，ABENAVOLI L，MYKHALCHYSHYN
tic for Non-alcoholic fatty liver disease[J]. Curr Pharm G，et al. A multi-strain probiotic reduces the fatty liver
Biotechnol，2024，25（4）：426-433. index，cytokines and aminotransferase levels in NAFLD
[ 9 ] FANG J，YU C H，LI X J，et al. Gut dysbiosis in nonalco‐ patients：evidence from a randomized clinical trial[J]. J
holic fatty liver disease：pathogenesis，diagnosis，and Gastrointestin Liver Dis，2018，27（1）：41-49.
therapeutic implications[J]. Front Cell Infect Microbiol， [20] KOBYLIAK N，ABENAVOLI L，FALALYEYEVA T，
2022，12：997018. et al. Beneficial effects of probiotic combination with
[10] HIGGINS J P T，ALTMAN D G，GØTZSCHE P C，et al. omega-3 fatty acids in NAFLD：a randomized clinical
The Cochrane collaboration’s tool for assessing risk of study[J]. Minerva Med，2018，109（6）：418-428.

中国药房 2024年第35卷第13期 China Pharmacy 2024 Vol. 35 No. 13 · 1649 ·